Skip to main content

Day: March 27, 2024

Valoe Corporation’s Financial Statement Release 2023

  Valoe Corporation        Financial Statement Release        27 March 2024 at 15.45 Finnish time THE FOURTH QUARTER IN BRIEF – RESTRUCTURING PROCEEDINGS COMMENCED During the fourth quarter of 2023, the net sales of Valoe Group, under the IFRS standards, was about EUR 0.01 million (in 2022: EUR 0.4 million). The EBITDA was EUR -0.8 million (EUR -1.2 million) and the EBIT EUR -1.1 million (EUR -1.7 million). The profit for the period was EUR -1.4 million (EUR -2.3 million). In the fourth quarter, the company’s financial situation remained very tight. The company sought to raise additional financing through the Convertible Bond 1/2023 issued in July 2023. The subscription period of the Convertible Bond continues until 31 July 2024. In addition, the company also entered into financing negotiations with several parties, and the negotiations...

Continue reading

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend

PALO ALTO, Calif., March 27, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the U.S. Bankruptcy Court for the Southern District of Texas (the “Court”) has extended the expiration of the restrictions on transfer of the shares of common stock of Scilex that were previously distributed by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), Scilex’s former controlling stockholder, to Sorrento’s stockholders as a dividend on January 19, 2023 (the “Dividend Stock”). Such lock-up period was previously set to expire on March 31, 2024. On March 26, 2024, the Court approved a motion to extend the lock-up period of the...

Continue reading

Metagenomi Reports Business Updates and Full Year 2023 Financial Results

Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024 Proof of capability demonstrated with CRISPR-associated transposase (CAST) system being developed to enable >10,000 base pair, targeted genomic integrations Ultra-small base editing systems (SMART) are the smallest nickase-based systems characterized to-date, designed to enable more efficient delivery via single adeno-associated viruses (AAVs) Closing of initial public offering provides cash runway to support 2 INDs and 2 additional Development Candidate nominations EMERYVILLE, Calif., March 27, 2024 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients...

Continue reading

21Shares Launches Revolutionary Toncoin Staking ETP (TONN) for Hassle-Free Staking Rewards

World’s largest issuer of cryptocurrency ETPs releases the 21Shares Toncoin Staking ETP ZURICH, March 27, 2024 – 21Shares AG (“21Shares”), the world’s largest issuer of cryptocurrency exchange traded products (ETPs) and a subsidiary of 21.co, proudly announces the launch of 21Shares Toncoin Staking ETP. This groundbreaking product provides investors with a seamless way to engage in the staking ecosystem and earn rewards effortlessly. The Toncoin Staking ETP presents an innovative solution for investors seeking exposure to staking rewards without the complexities of setting up and managing a staking node. With our ETP, investors can now enjoy the benefits of staking Toncoin while leveraging the liquidity and convenience of traditional financial markets. “Our 21Shares Toncoin Staking ETP opens up a new horizon for...

Continue reading

„Horizonterweiterung für Investoren“: 21Shares bringt Toncoin Staking-ETP auf dem Markt

Unkomplizierter Zugang zu Staking-Erträgen Zürich/München, 27. März 2024 – 21Shares AG, weltweit größter Anbieter von Krypto-ETPs und Tochtergesellschaft von 21.co, verkündet den Marktstart des 21Shares Toncoin Staking ETP, das mit dem heutigen Tag auf der Schweizer Börse SIX handelbar ist. Das Produkt bietet Anlegern eine Möglichkeit, sich unkompliziert am sogenannten Staking-Ökosystem zu beteiligen und damit auf mühelose Weise Prämien (Staking-Erträge) zu verdienen. Das Toncoin Staking ETP stellt eine innovative Lösung für Investoren dar, die von den Vorteilen des Staking der Kryptowährung Toncoin profitieren möchten – ohne dass dafür auf eigene sogenannte Staking-Nodes zurückgreifen müssen. Mittels des Toncoin Staking ETPs sind Staking-Erträge bei gleichzeitigem Erhalt von Liquidität und Komfort der traditionellen Finanzmärkte möglich. “Unser...

Continue reading

21Shares lancia un nuovo ETP su Toncoin, la criptovaluta degli sviluppatori di Telegram

Il più grande emittente di ETP su criptovalute al mondo ha quotato un prodotto sullo staking in ToncoinZurigo, 27 marzo 2024 – 21Shares, società con sede a Zurigo, sussidiaria di 21.co e leader nel segmento degli ETP sulle criptovalute con la più ampia gamma al mondo, annuncia oggi il lancio del nuovo 21Shares Toncoin Staking ETP (ticker: TONN) sulla piattaforma SIX Swiss exchange. Questo prodotto innovativo permetterà agli investitori di percepire un guadagno dallo staking in Toncoin in modo semplice e sicuro. Lo scopo dell’ETP è quello di offrire la possibilità di ottenere una remunerazione dal processo di staking senza dover essere gestori di un “nodo”, ovvero di quella struttura della blockchain che funge da punto di ingresso o di uscita dal sistema, indispensabile per l’approvazione delle transazioni. In questo modo, chi deciderà...

Continue reading

Eviden opens Security Operations Center in Mexico to enable advanced cybersecurity solutions for local organizations

Eviden LogoEviden LogoEviden’s 17th Security Operations Center located in Mexico to leverage global cybersecurity capabilities for real, local impact Paris, France – March 27, 2024 – Eviden, the Atos Group business leading in digital, cloud, big data and security, today announces the opening of its new Security Operations Center (SOC) in Monterrey, Mexico, to enable advanced cybersecurity services to organizations across North and South America. The Mexico center is Eviden’s 17th next-generation SOC worldwide, ultimately strengthening the powerful global SOC network. The increasing number of cyberattacks in today’s business environment are becoming more sophisticated. Eviden’s Security Operations Centers serve as a key differentiator to managing business risk by transforming security environments from highly siloed to holistic,...

Continue reading

Getty Images and United Football League Sign Multi-Year Renewal of Photography Partnership

A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) — Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, has been named the Official Photographic Agency of the United Football League (UFL). The UFL season kicks off on Saturday, March 30, 2024, when the Birmingham Stallions visit the Arlington Renegades at 1 PM ET. As part of the multi-year agreement, Getty Images’ award-winning sports photographers and editors will deliver high-quality imagery from every game during the 12-week season. This includes all on and off the field action, such as gameplay, warmups, fan interactions, celebrations and more, all to be distributed exclusively through gettyimages.com. “We are excited to partner with the United Football League and...

Continue reading

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has submitted a patent application under the international Patent Cooperation Treaty. The patent application refers to the novel proprietary composition of Clearmind’s MEAI compound (5-methoxy-2-aminoindane) with palmitoylethanolamide (“PEA”),...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.